We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Improvement in Health-Related Quality of Life Following Antibiotic Treatment in Nontuberculous Mycobacterial Pulmonary Disease: Initial Analysis of the NTM-KOREA Cohort.
- Authors
Kwak, Nakwon; Henkle, Emily; Hwang, Hyeontaek; Jeon, Doosoo; Jhun, Byung Woo; Jo, Kyung-Wook; Kang, Young Ae; Kim, Hyung-Jun; Kim, Joong-Yub; Kim, Young Ran; Kwon, Yong-Soo; Lee, Jae Ho; Mok, Jeongha; Park, Youngmok; Shim, Tae Sun; Sohn, Hojoon; Whang, Jake; Yim, Jae-Joon
- Abstract
Background Improving health-related quality of life (HRQOL) has emerged as a priority in the management of nontuberculous mycobacterial pulmonary disease (NTM-PD). We aimed to evaluate HRQOL and its changes after 6 months' treatment in patients with NTM-PD. Methods The NTM-KOREA is a nationwide prospective cohort enrolling patients initiating treatment for NTM-PD in 8 institutions across South Korea. We conducted the Quality of Life–Bronchiectasis (QOL-B) at 6-month intervals and evaluated baseline scores (higher scores indicate better quality of life) and changes after 6 months' treatment. Multivariate logistic regression was performed to identify factors associated with improvement in the QOL-B physical functioning and respiratory symptoms domains. Results Between February 2022 and August 2023, 411 patients were included in the analysis. Baseline scores (95% confidence interval [CI]) for physical functioning and respiratory symptoms were 66.7 (46.7–86.7) and 81.5 (70.4–92.6), respectively. Among 228 patients who completed the QOL-B after 6 months' treatment, improvements in physical functioning and respiratory symptoms were observed in 61 (26.8%) and 71 (31.1%) patients, respectively. A lower score (adjusted odds ratio; 95% CI) for physical functioning (0.93; 0.91–0.96) and respiratory symptoms (0.92; 0.89–0.95) at treatment initiation was associated with a greater likelihood of physical functioning and respiratory symptom improvement, respectively; achieving culture conversion was not associated with improvement in physical functioning (0.62; 0.28–1.39) or respiratory symptoms (1.30; 0.62–2.74). Conclusions After 6 months of antibiotic treatment for NTM-PD, HRQOL improved in almost one-third, especially in patients with severe initial symptoms, regardless of culture conversion. Clinical Trials Registration ClinicalTrials.gov identifier: NCT03934034.
- Subjects
SOUTH Korea; ANTIBIOTICS; MYCOBACTERIAL diseases; BRONCHIECTASIS; HEALTH status indicators; RESEARCH funding; LOGISTIC regression analysis; MULTIVARIATE analysis; DESCRIPTIVE statistics; TREATMENT effectiveness; LONGITUDINAL method; QUALITY of life; LUNG diseases; QUALITY assurance; CONFIDENCE intervals; DATA analysis software; TIME; PHYSICAL activity; EVALUATION
- Publication
Clinical Infectious Diseases, 2024, Vol 78, Issue 6, p1690
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciae131